Canada's Valeant Pharma posts quarterly net loss
Oct 31 (Reuters) - Valeant Pharmaceuticals International Inc , Canada's biggest publicly traded drugmaker, posted a quarterly net loss that it attributed in part to restructuring and impairment charges.
Valeant posted a net loss of $973 million, or $2.92 per share, for the third quarter, compared with a profit of $7.6 million, or 2 cents, a year earlier.
Cash earnings, or profit adjusted for one-time items, was $486 million, or $1.43 per share.
© Thomson Reuters 2017 All rights reserved.